From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Journal of Ophthalmology · 2026-01 · 2026 (1)
DOI: 10.1155/joph/2155378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ophthalmology, online erschienen am 22.04.2026. Verfasst von Wei-Xiang Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan, tzuchi.com.tw. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Tzu Chi Hospital.
Abstract (Originalsprache)
Purpose
To quantify the effects of lutein‐containing supplementation on structural and functional visual outcomes in patients with age‐related macular degeneration (AMD), with particular focus on disease stage and treatment exposure.
Methods
A meta‐analysis of randomized, placebo‐controlled trials was conducted. Nine RCTs involving 860 participants were included. Eligible studies evaluated oral lutein alone or in combination with zeaxanthin or epilutein and reported pre‐ and post‐treatment measurements of macular pigment optical density (MPOD) and best‐corrected visual acuity (BCVA). Random‐effects models were applied to calculate pooled effect sizes using Hedges’ g. Subgroup and meta‐regression analyses were performed to explore stage‐specific responses and dose‐duration associations.
Results
Across the 9 RCTs, lutein‐containing supplementation significantly improved MPOD (Hedges’ g = −0.589, p < 0.001) and BCVA (Hedges’ g = −0.827, p = 0.001). Improvements were predominantly observed in early‐stage AMD, whereas no statistically significant benefit was detected in late‐stage disease. Lutein monotherapy demonstrated greater visual benefit than combination regimens. Meta‐regression analyses revealed significant positive associations between treatment effect and both supplementation duration and total lutein exposure. Contrast sensitivity and serum lutein concentrations also improved significantly.
Conclusion
Lutein‐based supplementation is associated with measurable structural and functional visual benefits in early‐stage AMD. Treatment effects appear dose‐ and duration‐dependent, while evidence in late‐stage AMD remains limited. These findings support early intervention strategies and warrant further investigation into long‐term therapeutic impact.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Education, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan, tzuchi.com.tw.
- Department of Education, China Medical University Hospital, Taichung, Taiwan, cmu.edu.tw.
- Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan, tzuchi.com.tw.
ORCID-Profile: Wei-Xiang Wang, Chen-Chi Wang, Wei-Cherng Hsu, Yi-Jie Peng
Förderung
- Taipei Tzu Chi Hospital
Zitieren
APA
Wang, W. X., Wang, C. C., Hsu, W. C., & Peng, Y. J. (2026). From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Ophthalmology, 2026(1). https://doi.org/10.1155/joph/2155378
Vancouver
Wang WX, Wang CC, Hsu WC, Peng YJ. From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Ophthalmology. 2026;2026(1). doi:10.1155/joph/2155378
BibTeX
@article{Wang2026,
author = {Wang, Wei-Xiang and Wang, Chen-Chi and Hsu, Wei-Cherng and Peng, Yi-Jie},
title = {From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Journal of Ophthalmology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/joph/2155378}
}
EUVIMED